INFLAMASE MILD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for INFLAMASE MILD (INFLAMASE MILD).
Inflammase Mild is a combination product containing hydrocortisone, a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, thereby inhibiting the release of arachidonic acid and reducing prostaglandin and leukotriene synthesis. It also contains benzalkonium chloride, a quaternary ammonium compound with antiseptic properties.
| Metabolism | Hydrocortisone is primarily metabolized in the liver via reduction and conjugation; benzalkonium chloride is not significantly metabolized. |
| Excretion | Renal excretion of unchanged drug (approximately 60%) and glucuronide conjugate (20%); biliary/fecal (15%). |
| Half-life | 1.5-2.5 hours; short half-life allows frequent dosing for mild inflammation. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.15-0.20 L/kg; indicates low tissue distribution, primarily intravascular. |
| Bioavailability | Oral: 75-90%; Topical: approximately 5% systemic absorption. |
| Onset of Action | Oral: 30-60 minutes; Topical: within 1 hour. |
| Duration of Action | 4-6 hours for oral; topical duration varies with formulation, typically 4-8 hours. |
N/A
| Dosage form | SOLUTION/DROPS |
| Renal impairment | N/A |
| Liver impairment | N/A |
| Pediatric use | N/A |
| Geriatric use | N/A |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for INFLAMASE MILD (INFLAMASE MILD).
| Breastfeeding | Low levels in breast milk; M/P ratio 0.18. Considered compatible with breastfeeding due to short half-life and low infant dose. |
| Teratogenic Risk | In first trimester, risk of oral clefts and cardiovascular malformations; third trimester risk of premature ductus arteriosus closure and oligohydramnios. Avoid in third trimester. |
| Fetal Monitoring | Monitor fetal echocardiography for ductus arteriosus patency; amniotic fluid index for oligohydramnios; maternal renal function and blood pressure. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to any component","Corneal abrasion or ulcer","Viral or fungal eye infections","Untreated bacterial eye infections"]
| Precautions | ["Prolonged use may lead to increased intraocular pressure (IOP), glaucoma, cataract formation, or secondary ocular infections.","Do not use while wearing contact lenses.","If symptoms persist or worsen, discontinue use and consult a physician."] |
Loading safety data…
| Fertility Effects | May inhibit ovulation through prostaglandin synthesis inhibition; reversible upon discontinuation. |